Gen9 And SynbiCITE Announce Partnership to Accelerate Technology
News Feb 22, 2016
Gen9 and SynbiCITE have announced a partnership that provides members of the SynbiCITE research community access to Gen9’s high-throughput BioFab® platform for gene synthesis.“Synthetic biology has been named one of the eight great British technologies of the future. It has enormous potential to advance the research of our members who are working on many societal challenges, from pollution to hunger to disease,” said John Collins, Ph.D., Commercial Director at SynbiCITE.
“Gen9’s DNA synthesis technologies will be an invaluable resource to our members. These types of industry partnerships enable faster commercialization of breakthrough technologies in the space.”Since 2013, SynbiCITE has been fostering innovation and collaboration with a goal of accelerating the commercialization of synthetic biology products, tools and processes.
Members receive access to education, funding opportunities, laboratory facilities and the latest synthetic biology technologies. SynbiCITE is funded by the UK Research Councils, Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (BBSRC), Innovate UK, and its industrial and academic partners.
Central to the Gen9 and SynbiCITE collaboration is Gen9’s BioFab® platform for manufacture of high-quality, low-cost synthetic DNA at unprecedented scale and accuracy. With access to this technology, scientists can design more powerful experiments and test many hypotheses simultaneously, resulting in faster and more effective research outcomes.
“Our mission is to empower scientists through the limitless possibilities of synthetic biology,” said Kevin Munnelly, President and CEO of Gen9. “We are excited to collaborate with SynbiCITE, a visionary organization that shares our goal of making synthetic biology accessible to all researchers. We look forward to the cutting-edge advancements that will be realized through our partnership.”
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE